Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Patent
1999-01-29
2000-04-04
Mosher, Mary E.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
A61K 3912
Patent
active
060458038
ABSTRACT:
The live recombinant avian vaccine comprises, as vector, an avian herpesvirus comprising at least one nucleotide sequence coding for and expressing an antigenic polypeptide of an avian pathogenic agent, inserted into the region lying between the ATG of ORF UL55 and the junction of U.sub.L with the adjacent repeat region, under the control of the CMV immediate early promoter. The vector is preferably chosen from the group consisting of Marek's disease viruses (MDV and HVT), infectious laryngotracheitis virus ILTV and herpes of ducks. A polyvalent vaccine formula comprises at least two vaccines of this type, with different inserted sequences.
REFERENCES:
patent: 5853733 (1994-08-01), Cochran et al.
Audonnet Jean-Christophe Francis
Bublot Michel Joseph Marie
Darteil Raphael Jean
Duinat Carole Veronique
Laplace Eliane Louise Fran.cedilla.oise
Frommer William S.
Kowalski Thomas J.
Merial
Mosher Mary E.
LandOfFree
Live recombinant avian vaccine using an avian herpesvirus as vec does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Live recombinant avian vaccine using an avian herpesvirus as vec, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Live recombinant avian vaccine using an avian herpesvirus as vec will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-362349